|
Medical News -
Allergy
|
|
Edith Hessel and colleagues, at Dynavax Technologies Corporation, Berkeley, have identified the reason that humans and rodents respond differently to a molecule that is being developed to treat allergic diseases. Molecules that trigger the protein TLR9 are being developed as a potential therapeutic for allergic diseases. While they have been shown to be safe and well-tolerated when inhaled by people, they cause severe lung inflammation and toxicity when inhaled by rodents. Read more:
|
